Development

Applying theoretical physics to Longevity drug discovery

Peter Fedichev's Gero raising $10 million for anti-aging drug discovery and clinical trials. The use of AI in Longevity drug discovery is nothing new, Insilico...

Telomeres – it’s not the end of the line

Sigh of relief as new study identifies possible drug treatments for telomere diseases – are we finally edging closing to unlocking the potential of...

Longevity and the art of motorcycle maintenance

OpenCures' Kevin Perrott talks about empowering the consumer with their own health data. One of the Longevity sector’s leading voices came to the field relatively...

BioAge licenses HIF-PH inhibitor to treat aging

BioAge's human aging data platform demonstrates that HIF pathway is linked to healthspan and lifespan. Longevity focused biotech firm BioAge Labs has announced an exclusive...

Longevity2020: Day 3 recap

Experts, innovators, investors and the curious meet online in the biggest Longevity conference ever staged. As we enter the fourth day of Longevity2020, we thought...

Longevity2020: Day 2 recap

Yesterday at Longevity2020 was all about rejuvenation therapies, bringing together some of the world’s leading luminaries in the fight against aging. Things kicked off with...

Longevity2020: Day 1 recap

The first day of Longevity2020 kicked off yesterday as we welcomed some of the big names in Longevity to the virtual stage. Curated by AgeCurve’s...

Margaretta Colangelo on Longevity2020

An in-depth preview of big-hitting AI speakers at the first ever online Longevity conference. It's finally here - Longevity2020 week has arrived! Later today, we...

BioViva to spin out its R&D and bioinformatics

CEO in the front-line: Liz Parrish talks gene therapy, patient data and funding. From academics and entrepreneurs to engineers and technologists, the battle against aging...

Oisín on aging as a disease and raising $5m seed

Co-founder Gary Hudson talks cell senescence, trials, spin-outs and the dilemma of treating age as a disease. Every entrepreneur in Longevity has a different story...

Juvenescence CEO on near-term Longevity breakthroughs

We talk pipeline, trials, raising capital and public company challenges with Juvenescence's Dr Greg Bailey. Longevity.Technology: Longevity is growing as a distinct investment category and Thursday’s...

Insilico teams up with Boehringer Ingelheim on drug discovery

Research collaboration to apply generative AI system for discovery of potential therapeutic targets. Artificial intelligence company Insilico Medicine has announced a research collaboration with pharmaceutical...

Building faster and better age-related clinical trials

Prof Ilaria Bellantuono seeks to build faster, better clinical trials for age-related disease with a focus on frailty. Multimorbidity – an individual suffering two or...

COVID-19: Leading clinician calls for focus on the biology of aging

Dr Nir Barzilai predicts that rapamycin could decrease severity of coronavirus in the elderly by 50%. Longevity.Technology: When it comes to the world of Longevity...

Early intervention and disease prevention = Longevity

Talking prevention and treatments for Longevity with Prodrome's Dayan Goodenowe. Detecting prodromes – an early indication of a developing condition or disease – could revolutionise...

Chemical screening to find hidden Longevity gems?

Start-up NemaLife evolves from platform technology to services provider to identify chemicals that have both positive and negative effects on Longevity. The use of the...

From machines to animals to humans

Exclusive with Prof Joao Pedro de Magalhaes: talking AI, indication expansion and animal models. “Will you still need me, will you still feed me, when...

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

Indication expansion to meet Longevity market demand

Several compounds have demonstrated life-extending effects in animal models, some of which are currently being tested for their ability to exert anti-aging effects in...

Alkahest Parkinson’s clinical trial gets funding boost

Alkahest announced today that they have initiated a phase 2 clinical trial with funding from the Michael J. Fox Foundation (MJFF). Today's press release reveals...

Latest articles

Building an artificial immune system

DoD-funded ThirdLaw Technologies to harness the power of ‘spiroligomers’ to rapidly build new small molecules for Longevity therapies. Far from the world of stock market...

Neurotech is the new blue ocean

Alon Braun, Co-Founder, Neurotech Analytics.

Amazon and K4Connect demonstrate scalability for agetech

Covid-19 has been difficult for everyone, but particularly for people over the age of 65 who may spend months shut away from loved ones...

“Avoid the use of DQ as a senolytic therapy”

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic. The Forever Healthy Foundation today published its latest risk-benefit analysis, which explores...